Overview

Clinical Trial of a COX-2 Inhibitor for the Treatment of Women With Preeclampsia

Status:
Withdrawn
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Preeclampsia is a hypertensive disorder of pregnancy and a leading cause of fetal and maternal morbidity and mortality. Recent findings indicate preeclampsia is an inflammatory disorder associated with increased expression of COX-2. This study will test the hypothesis that treatment of women with a COX-2 inhibitor, celecoxib, will stop the inflammatory process and reverse symptoms of preeclampsia.
Phase:
Phase 2
Details
Lead Sponsor:
Virginia Commonwealth University
Treatments:
Celecoxib
Cyclooxygenase 2 Inhibitors